Synergy Pharmaceuticals Reports Third Quarter 2012 Financial Results

Synergy Pharmaceuticals Reports Third Quarter 2012 Financial Results

Synergy Advances Clinical Programs

NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc.
(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders
and diseases, today reported its financial results and business update for the
third quarter and nine month ended September 30, 2012. Synergy is developing
plecanatide for the treatment of chronic idiopathic constipation (CIC) and
constipation-predominant irritable bowel syndrome (IBS-C).

"The third quarter of 2012 has been the most productive and exciting quarter
in our history," said Gary S. Jacob, Ph.D., President and CEO of Synergy.
"During this period, we successfully completed enrollment, totaling 951
patients, in our plecanatide Phase IIb/III clinical trial in CIC patients, and
are on track to complete last visit in all patients by December 7. After that
we will lock the database, analyze the data, and expect to release top-line
data during the first week of January 2013. This has all been accomplished by
a highly focused and dedicated Synergy team driven to provide new treatments
for people suffering from GI disorders and diseases."

"We also finalized preparations for the start-up of our plecanatide Phase IIb
trial in IBS-C patients which is scheduled to get started shortly," stated Dr.
Jacob."Also, during the month of October, our second GC-C receptor agonist
drug candidate, SP-333, began a Phase I clinical trial in volunteers."

Recent Developments

  *On July 20, 2012, Synergy Signs Definitive Agreement to Acquire Callisto
    Pharmaceuticals, as Amended October 15, 2012.
  *On August 14, 2012, Synergy Announces Enrollment in Phase IIb/III Study in
    CIC Patients will be completed at end of August.
  *On August 17, 2012, Synergy Pharmaceuticals Acquires FV-100 Shingles Drug
    From Bristol-Myers Squibb Company.
  *On September 7, 2012, Synergy files IND for SP-333, a Developmental Drug
    for Gastrointestinal Diseases.
  *On September 14, 2012, Synergy enters into a binding letter of intentwith
    Ironwood Pharmaceuticals, Synergy an exclusive worldwide
    license to Ironwood's method of use patent on plecanatide.
  *On October 19, 2012, Synergy Initiates Dosing of Healthy Volunteers in
    Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat
    Ulcerative Colitis.

Financial Update

Synergy's cash and cash equivalents balance as of September 30, 2012 was $37.4
million, including available for sale securities, as compared to $13.2 million
on December 31, 2011. During the nine months ended September 30, 2012 and 2011
net cash provided by financing activities was $48.2 million and $7.8 million,
respectively. Net cash used in operating activities during the nine months
ended September 30, 2012 and 2011 was $23.1 million and $9.7 million,
respectively. Net loss for the nine months ended September 30, 2012 was $27.5
million or $0.46 per share, as compared to a net loss of $8.8 million, or
$0.19 per share, for the nine months ended September 30, 2011.

Net loss for the quarter ended September 30, 2012 was $9.9 million, or $0.15
per share, as compared to a net loss of $0.6 million, or $0.01 per share, for
the quarter ended September 30, 2011. During the quarter ended September 30,
2011 Synergy reported a $4.4 million gain from the change in fair value of
derivative instruments, whereas such gain was $0.1 million this quarter.

Synergy had approximately 65.8 million common shares outstanding at September
30, 2012.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs
to treat gastrointestinal disorders and diseases. Synergy's lead proprietary
drug candidate plecanatide is a synthetic analog of the human gastrointestinal
(GI) hormone uroguanylin, and functions by activating the guanylate cyclase C
receptor on epithelial cells of the GI tract. Synergy completed a Phase I
study of plecanatide in healthy volunteers and a Phase IIa clinical trial in
chronic idiopathic constipation (CIC) patients. In October, 2011, Synergy
initiated dosing of patients in a major Phase IIb/III clinical trial of
plecanatide to treat CIC. Plecanatide is also being developed to treat
constipation-predominant irritable bowel syndrome (IBS-C), with the first
trial in IBS-C patients planned for the second half of 2012. Synergy's second
GC-C agonist SP-333 is in clinical development to treat inflammatory bowel
diseases, and is presently in a Phase I trial in healthy volunteers. More
information is available at

Forward-Looking Statements

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "planned," "believe," "forecast," "estimated," "expected," and
"intend," among others. These forward-looking statements are based on
Synergy's current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, substantial competition; our ability
to continue as a going concern; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of government
or third party payer reimbursement; limited sales and marketing efforts and
dependence upon third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations. As with any
pharmaceutical under development, there are significant risks in the
development, regulatory approval and commercialization of new products. There
are no guarantees that future clinical trials discussed in this press release
will be completed or successful or that any product will receive regulatory
approval for any indication or prove to be commercially successful. Investors
should read the risk factors set forth in Synergy's Form 10-K for the year
ended December 31, 2011 and other periodic reports filed with the Securities
and Exchange Commission. While the list of factors presented here is
considered representative, no such list should be considered to be a complete
statement of all potential risks and uncertainties. Unlisted factors may
present significant additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as of the date
hereof, and Synergy does not undertake any obligation to update publicly such
statements to reflect subsequent events or circumstances.

Condensed Consolidated Balance Sheets ($ in thousands)
(unaudited)                               September 30, 2012 December 31, 2011
Cash, cash equivalents and available for  $37,367            $13,245
sale securities
Prepaid expenses and other current assets 1,285              1,063
Total current assets                      38,652             14,308
Other assets                              2,678              1,562
Total assets                              $41,330            $15,870
Liabilities and Stockholders' Equity                        
Accounts payable                          $2,506             $1,416
Accrued expenses                          2,470              1,331
Total current liabilities                 4,976              2,747
Derivative financial instruments          4,663              3,325
Total Liabilities                         9,639              6,072
Total stockholders' equity                31,691             9,798
Total liabilities and stockholders'       $41,330            $15,870

Condensed Consolidated Statement of Operations
($ in thousands except Three Months  Three Months  Nine Months   Nine Months
per share data)        ended         ended         ended         ended
(unaudited)            September 30, September 30, September 30, September 30,
                       2012          2011          2012          2011
Revenues               $ --          $ --          $ --          $ --
Costs and Expenses:                                           
Research and           8,246         3,883         21,210        7,715
General and            1,843         1,103         5,493         4,525
Loss from Operations   (10,089)      (4,986)       (26,703)      (12,240)
Other income           --            --            256           
Interest and           63            20            150           64
investment income
Interest expense       --            --            --            (12)
Change in Fair Value
of Financial           141           4,383         (1,169)       3,346
Net Loss               ($9,885)      ($583)        ($27,466)     ($8,842)
Net Loss per common
share, basic and       ($0.15)       ($0.01)       ($0.46)       ($0.19)
Weighted Average
Common Shares          65,806        47,309        60,194        46,708
Outstanding (a)
(a) Weighted average shares outstanding reflects retroactive change of a one
for two (1:2) reverse stock split effective on November 30, 2011

CONTACT: Investor Contact Information:
         Danielle Spangler
         The Trout
         (646) 378-2924
Press spacebar to pause and continue. Press esc to stop.